You just read:

CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.

News provided by

CytRx Corporation

Oct 12, 2017, 09:00 ET